About Pediatric Medicines
The pediatric drug market plays a pivotal role in the pharmaceutical industry. There are several vendors, who provide healthcare services and products for pediatric population. The pediatric medicines market is one of the important segments in the pharmaceutical industry. Infants are prone to infections owing to their under-developed immune system. The presence of a large pediatric population, especially in APAC combined with the population being more prone to infections and illness will increase the demand for pediatric medicines.
The pediatric medicines market is one of the emerging markets in the pharmaceutical sphere with huge unmet needs and requires support for better innovation and higher R&D investments.
Technavio’s analysts forecast the global pediatric medicines market to grow at a CAGR of 4.97% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global pediatric medicines market for 2017-2021. To calculate the market size, the report considers the sales of vaccines, branded, generic, and off-label drugs.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Pediatric Medicines Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• GSK
• Novartis
• Pfizer
• Sanofi
Other prominent vendors
• Abbott
• Bristol-Myers Squibb
• Cipla
• Eisai Pharmaceuticals
• Eli Lilly
• F. Hoffman-La Roche
• Glenmark
• Helsinn Healthcare
• Heron Therapeutics
• Ipca Laboratories
• Lupin Pharmaceuticals
• Merck Sharp & Dohme
• RedHill
• Sun Pharmaceutical Industries
• Takeda Pharmaceutical
Market driver
• High pediatric population
• For a full, detailed list, view our report
Market challenge
• Usage of off-label drugs
• For a full, detailed list, view our report
Market trend
• Inorganic growth strategies
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
PART 05: Market overview
• Five forces analysis
PART 06: Pipeline analysis
• Phase I molecules
• Phase II molecules
• Phase III molecules
PART 07: Market segmentation by Route of drug administration
• Enteral RoA
• Parenteral RoA
• Topical RoA
PART 08: Market segmentation by disease type
• Respiratory diseases
• Infectious diseases
• Gastrointestinal diseases
• CNS diseases
• Oncological diseases
• CVDs
• Others
PART 09: Geographical segmentation
• Pediatric medicines market in Americas
• Pediatric medicines market in EMEA
• Pediatric medicines market in APAC
PART 10: Drivers and challenges
• Market drivers
• Market challenges
• Oral soluble films
PART 11: Market trends
• Inorganic growth strategies
• Government initiatives
PART 12: Vendor landscape
• Competitive scenario
PART 13: Key vendor analysis
• GSK
• Novartis
• Pfizer
• Sanofi
• Other prominent vendors
PART 14: Appendix
• List of abbreviations
List of Exhibits
Exhibit 01: Factors influencing the global pediatric medicines market
Exhibit 02: Key focused therapeutic areas in global pediatric medicines market
Exhibit 03: Major acute pediatric diseases
Exhibit 04: Major chronic pediatric diseases
Exhibit 05: Global pediatric medicines market: Major growth drivers
Exhibit 06: Global pediatric medicines market 2016-2021 ($ billions)
Exhibit 07: Opportunity analysis in global pediatric medicines market
Exhibit 08: Five forces analysis
Exhibit 09: Phase I: Key molecules by vendors
Exhibit 10: Phase I: Key molecules landscape
Exhibit 11: Phase II: Key molecules by vendors
Exhibit 12: Phase II: Key molecules landscape
Exhibit 13: Phase III: Key molecules by vendors
Exhibit 14: Phase III: Key molecules landscape
Exhibit 15: Market segmentation by RoA 2016
Exhibit 16: Characteristics of enteral RoA
Exhibit 17: Global pediatric enteral medicines market 2016-2021 ($ billion)
Exhibit 18: Advantages of liquid dosage form over other enteral routes
Exhibit 19: Global pediatric parenteral medicines market 2016-2021 ($ billion)
Exhibit 20: Various routes of parenteral route administration
Exhibit 21: Various formulations of topical administration
Exhibit 22: Global pediatric topical medicines market 2016-2021 ($ billion)
Exhibit 23: Advantages of topical route of drug administration
Exhibit 24: Global pediatric medicines market segmentation by disease type
Exhibit 25: Various types of respiratory diseases in pediatric population
Exhibit 26: Various types of infectious diseases in pediatric population
Exhibit 27: Various types of gastrointestinal diseases in pediatric population
Exhibit 28: Various types of CNS disorders in Pediatric patients
Exhibit 29: Major oncological disorders seen in pediatric patients
Exhibit 30: Various types of CVDs in pediatric patient
Exhibit 31: Segmentation of global pediatric medicines market by geography 2016 and 2021
Exhibit 32: Global pediatric medicines market by geography 2016-2021 ($ billions)
Exhibit 33: Market scenario in Americas
Exhibit 34: Pediatric medicines market in Americas 2016-2021 ($ billions)
Exhibit 35: Market scenario in EMEA
Exhibit 36: Pediatric medicines market in EMEA 2016-2021 ($ billion)
Exhibit 37: Market Scenario in APAC
Exhibit 38: Pediatric medicines market in APAC 2016-2021 ($ billion)
Exhibit 39: Pediatric population in US 1980-2050
Exhibit 40: Few phase III molecules for pediatric application
Exhibit 41: Few commonly used off-label drugs for pediatric patients
Exhibit 42: Various challenges in pediatric clinical trials
Exhibit 43: Inorganic growth strategies
Exhibit 44: Various government initiatives
Exhibit 45: Competitive structure analysis of global pediatric medicines market 2016
Exhibit 46: Market penetration of various pediatric medicines manufacturers worldwide 2016
Exhibit 47: Strategic success factors of companies in global pediatric medicines market
Exhibit 48: GSK: Key highlights
Exhibit 49: GSK: Strength assessment
Exhibit 50: GSK: Strategy assessment
Exhibit 51: GSK: Opportunity assessment
Exhibit 52: Novartis: Key highlights
Exhibit 53: Novartis: Strength assessment
Exhibit 54: Novartis: Strategy assessment
Exhibit 55: Novartis: Opportunity assessment
Exhibit 56: Pfizer: Key highlights
Exhibit 57: Pfizer: Strength assessment
Exhibit 58: Pfizer: Strategy assessment
Exhibit 59: Pfizer: Opportunity assessment
Exhibit 60: Sanofi: Key highlights
Exhibit 61: Sanofi: Strength assessment
Exhibit 62: Sanofi: Strategy assessment
Exhibit 63: Sanofi: Opportunity assessment
